New Website Aids in the Cattle Industry’s Fight to Eradicate BVDV 

 

DULUTH, Georgia  — Bovine viral diarrhea virus (BVDV) continues to challenge the cattle industry across the United States. Losses from just one BVDV case can cost up to $400.1 The virus often goes undiagnosed, but the consequences are severe, including losses from infertility, pneumonia, abortions, stillbirths, weak or deformed calves and immunosuppression.1

 

To help producers take on this ongoing challenge, BVDVTracker.com was launched. The website’s mission is to support veterinarians, producers and industry professionals in the control of BVDV across the United States. BVDVTracker.com was developed with three defining features:

 

1. Nationwide heat map

BVDVTracker.com includes an interactive heat map that makes it easy to identify if BVDV Type 1b is impacting your area. Type 1b is the most prevalent subtype of BVDV in the nation.2 Knowing the specific subtype can help direct prevention and vaccination decisions. 

 

 


 

2. Veterinarians and producers can report a BVDV case

Think BVDV is in your herd? You can request to submit an anonymous sample to test for infection through BVDVTracker.com. There is no treatment for BVDV, but diagnostic testing can guide successful vaccination programs. All samples submitted through BVDVTracker.com are processed by the Animal Disease Research and Diagnostic Laboratory at South Dakota State University.

 

3. BVDV resource library

BVDV spreads easily and can span a lifetime, throughout all segments of animal development. That’s why BVDVtracker.com includes comprehensive information from industry experts on detection, prevention and treatment. 

 

Boehringer Ingelheim created BVDVTracker.com as a tool for industry professionals in the surveillance and management of BVDV across the United States. They believe the best way to run a cattle operation is by putting the health and well-being of the animal at the top of the priority list. To find out more, visit BVDVTracker.com. 

 

 

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.

 

Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

 

About Boehringer Ingelheim

 

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.

 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

 

©2019 Boehringer Ingelheim Animal Health USA Inc. US-BOV-0034-2019